Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Koneksa Health Announces Study Publication Validating mHealth Technologies in Early-Stage Clinical Trial Safety Monitoring

PR Newswire January 24, 2020

Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

Canada NewsWire January 23, 2020

BriaCell Invited to Present at Mount Sinai's Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

GlobeNewswire January 22, 2020

FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

Business Wire January 21, 2020

Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellbeing Among Veterinarians

PR Newswire January 18, 2020

Merck Completes Acquisition of ArQule

Business Wire January 16, 2020

FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review

Business Wire January 13, 2020

BriaCell Provides Update on Remarkable Responder

GlobeNewswire January 13, 2020

BriaCell Outlines New High Responding Patient Group 'Biomarker' Based on Cancer Grade

GlobeNewswire January 9, 2020

FDA Approves Merck's KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy

Business Wire January 8, 2020

Merck's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Business Wire January 6, 2020

Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm

PR Newswire January 6, 2020

Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

Business Wire January 6, 2020

Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5

Business Wire January 3, 2020

BriaCell Completes Share Consolidation

GlobeNewswire January 2, 2020

Merck to Present at the 38th Annual J.P. Morgan Healthcare Conference

Business Wire January 2, 2020

LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

Business Wire December 30, 2019

BriaCell Therapeutics Corp. Announces Share Consolidation

GlobeNewswire December 24, 2019

NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)

GlobeNewswire December 20, 2019

Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live)

Business Wire December 20, 2019